<?xml version="1.0" encoding="UTF-8"?>
<p id="Par51">At present, many research teams worldwide are focused on the development of drugs for the prevention and treatment of COVID-19 (ref.
 <sup>
  <xref ref-type="bibr" rid="CR41">41</xref>
 </sup>). Of note, the development and testing of new drugs are time-consuming processes
 <sup>
  <xref ref-type="bibr" rid="CR139">139</xref>
 </sup> and not a viable strategy during this COVID-19 pandemic. Drug repurposing
 <sup>
  <xref ref-type="bibr" rid="CR139">139</xref>
 </sup>, in which existing medications that have already been approved for a disease are tested for a new condition, is currently the main approach in the search for new drugs for COVID-19 (refs
 <sup>
  <xref ref-type="bibr" rid="CR41">41</xref>,
  <xref ref-type="bibr" rid="CR42">42</xref>,
  <xref ref-type="bibr" rid="CR140">140</xref>,
  <xref ref-type="bibr" rid="CR141">141</xref>
 </sup>). However, some of the drugs under investigation have known or unknown cardiovascular adverse effects
 <sup>
  <xref ref-type="bibr" rid="CR142">142</xref>
 </sup> or might be involved in drug–drug or drug–disease interactions
 <sup>
  <xref ref-type="bibr" rid="CR41">41</xref>,
  <xref ref-type="bibr" rid="CR140">140</xref>
 </sup> (Table 
 <xref rid="Tab2" ref-type="table">2</xref>).
</p>
